The EU's CHMP has endorsed Amgen's Prolia (denosumab) for the treatment of osteoporosis in postmenopausal women at risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Once approved, the drug could become the first biological agent to carry an indication for osteoporosis; there are also no...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?